

61
67. The kit according to claim 65, wherein the antibody is a monoclonal antibody.--

REMARKS

Claims 1 to 52 have been cancelled without prejudice or disclaimer. New claims 53 to 67 have been added. Upon entry of this Amendment, claims 53-67 will be pending in this divisional application filed under 37 C.F.R. § 1.53(d) on August 29, 2001.. Support for claims 53-67 may be found in the specification. For example, the specification states on page 15, lines 19-23: “[p]olypeptide products of the invention may be “labeled” by association with a detectable marker substance (e.g., radiolabeled with ^{125}I) to provide reagents useful in detection and quantification of MI in solid tissue and fluid samples such as blood or urine.” Support for claims 53-67 also may be found in the specification on page 17, lines 32-35; beginning on page 18, line 31, to page 19, line 17; and in Example 6. No new matter has been added.

If there is any fee due in connection with the filing of this Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 3, 2001

By: 

William L. Strauss
Reg. No. 47,114